Vemlidy made 'unviable': Gilead

Posted 5 November 2020

Gilead Sciences has used a submission to the Zimmerman parliamentary inquiry to lift 'the cone of silence' on the status of two of its medicines -  hepatitis B drug, Vemlidy which has been waiting for a PBS listing for more than three years and new CAR -T cell therapy, Yescarta which has been languishing without Federal Government funding for 10 months.

Vemlidy takes the prize for waiting the longest time for a PBS listing with no result, three years and nine months since its submission to the PBAC, even though Australians living with chronic hepatitis B have not had access to a new therapeutic since 2009.

To see the whole article, please login